Watch our webinar with Prescient Therapeutics, featuring Prescient CEO and MD Steven Yatomi-Clarke. Steven will be holding a webinar to outline the company’s diversified portfolio of later stage and emerging assets for cancer treatment. A presentation followed by live Q&A with the audience.

Prescient Therapeutics (ASX: PTX) is emerging as a key player of the cell therapy revolution, featuring a broad portfolio of well-advanced assets developed with world-leading partners, including Yale, UPenn, Oxford University and Peter MacCallum.
Prescient’s world-class portfolio boasts a diversified range of assets with two first-in class targeted therapies, PTX-100 and PTX-200, that are currently in clinical development and showing encouraging activity in diseases of unmet need. Prescient owns the exclusive rights to two vital CAR-T platform technologies, OmniCAR and CellPryme - both with the potential to elevate and enhance CAR-T therapies - effectively giving them a ‘shovels to the gold rush’ advantage in a burgeoning area of cancer treatment.
Management tells one side of the story. Sharewise clients get independent research and Advisor access across ASX, US and global markets.